[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"pneumothorax-spontaneous-secondary\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:pneumothorax-spontaneous-secondary":26},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,3,0,[8,47,76],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":13,"acronym":4,"eligibilityCriteria":14,"healthyVolunteers":11,"sex":15,"minAge":16,"maxAge":4,"enrollmentInfo":17,"targetDuration":4,"studyType":20,"phases":21,"briefSummary":23,"conditions":24,"keywords":29,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":35,"lastUpdatePostDateStruct":36,"startDateStruct":39,"completionDateStruct":41,"leadSponsor":43,"locationsCount":46},"100605858","comparison-of-talc-slurry-versus-talc-insufflation-a-study-on-effectiveness-safety-and-hospital-outcomes-in-pleurodesis-100605858",false,"NCT07167992","Comparison of Talc Slurry Versus Talc Insufflation: A Study on Effectiveness, Safety, and Hospital Outcomes in Pleurodesis","Inclusion Criteria:\n\n* patients aged 12 years and older.\n* Diagnosed with malignant pleural effusions or pneumothoraces.\n* ECOG performance status of 0-2.\n* Life expectancy of at least 3 months.\n* Ability to provide informed consent.\n* No contraindications to general anesthesia or conscious sedation.\n\nExclusion Criteria:\n\n* Patients younger than 12 years old\n* Female patients who are pregnant or lactating\n* Patients with encysted or septated pleural effusions and pneumothoraces\n* Patients presenting with respiratory failure\n* Patients complaining of dyspnea in spite of complete evacuation of pleural effusion or pneumothorax.\n* Patients with evident chest infection with clinical or laboratory signs suggestive of parapneumonic effusions.","ALL","12 Years",{"count":18,"type":19},160,"ESTIMATED","INTERVENTIONAL",[22],"NA","Pleural effusion is characterized by the accumulation of fluid in the pleural space, which typically contains about 10-20 mL of pleural fluid that is crucial for the movement of the lungs against the chest wall. This fluid closely resembles plasma but has a lower protein concentration, usually less than 1.5 gm\u002FdL. It primarily originates from pleural capillaries and the interstitial spaces of the lung, and is reabsorbed through the lymphatic vessels in the parietal pleura, either via small openings known as stomas or through a process called transcytosis (1, 2). When the balance between fluid production and reabsorption is disrupted-often due to various pathogenic mechanisms-it can lead to pleural effusion. In such cases, effective management is essential. This study aims to conduct a thorough comparison of the two talc administration methods-TS and TI-using sterilized, large-particle, asbestos-free talc powder. By examining key outcome measures such as pleurodesis success rates, procedural morbidity, and length of hospital stay, the goal is to provide clinicians with evidence-based guidance to facilitate informed decision-making in the management of pleural effusions.",[25,26,27,28],"Pneumothorax Spontaneous Primary","Pneumothorax Spontaneous Secondary","Pleural Effusion, Malignant","Pleurodesis",[30,31,28,32,33],"Talc slurry","Talc Insufflation","malignant pleural effusions","recurrent pneumothorax","NOT_YET_RECRUITING","2026-01-03",{"date":37,"type":38},"2026-01-06","ACTUAL",{"date":40,"type":19},"2026-02-01",{"date":42,"type":19},"2027-03-30",{"name":44,"class":45},"University of Health Sciences Lahore","OTHER",1,{"id":48,"slug":49,"hasResults":11,"nctId":50,"briefTitle":51,"officialTitle":52,"acronym":53,"eligibilityCriteria":54,"healthyVolunteers":11,"sex":15,"minAge":55,"maxAge":4,"enrollmentInfo":56,"targetDuration":4,"studyType":20,"phases":58,"briefSummary":61,"conditions":62,"keywords":63,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":67,"lastUpdatePostDateStruct":68,"startDateStruct":70,"completionDateStruct":72,"leadSponsor":74,"locationsCount":4},"100583965","phase-2-stop-air-leak-by-talc-or-autologous-blood-patch-therapy-100583965","NCT06883188","Stop Air Leak by Talc or Autologous Blood Patch Therapy","A Pilot Randomised Study Comparing the Clinical Efficacy of Stopping Air Leak by Talc Pleurodesis or Autologous Blood Patch Therapy in Secondary Spontaneous Pneumothorax","STOP","Inclusion Criteria:\n\n* Age 18 years or older\n* Radiographically proven pneumothorax and underlying lung disease (either pre-existing or shown in diagnostic imaging at presentation)\n* Spontaneous onset of pneumothorax, not related to trauma or iatrogenic procedure\n* SSP with air leak persists for ≥3 days after the first radiographic evidence of pneumothorax\n* Intend to administer talc or autologous blood patch therapy (ABPT) to stop the air leak as the next step of treatment\n\nExclusion Criteria:\n\n* A chest drain size smaller than Fr 12\n* Bilateral pneumothorax\n* Impaired blood clotting, including baseline INR \\> 1.5, platelet \\\u003C 150 x 10\\^9\u002FL, use of therapeutic dose anticoagulant or dual-antiplatelet agents\n* Active or recent (within 6 weeks) pleural infection\n* Septicaemia or active extrapleural infection (e.g. pneumonia)\n* Use of long-term systemic corticosteroids or immunosuppressant\n* Previously received talc or ABPT to the ipsilateral pleural space for the current episode of pneumothorax\n* Known sensitivity to talc\n* Has had a previous pneumonectomy (either on the same or contralateral side)\n* Patients who are pregnant or lactating (females of childbearing potential must have a negative pregnancy test before randomisation)\n* Expected survival of less than three months from a different pathology to this pneumothorax (e.g. metastatic malignancy)\n* Cognitively impaired and physically unable to follow the turning procedure during intrapleural procedure, or at risk of self-removing chest drain\n* Inability to give informed consent","18 Years",{"count":57,"type":19},30,[59,60],"PHASE2","PHASE3","Objectives: To compare the therapeutic efficacy and safety profiles of intrapleural talc pleurodesis versus autologous blood patch therapy(ABPT) in patients with secondary spontaneous pneumothorax(SSP) complicated by persistent air leak(PAL), and to assess the trial feasibility for a subsequent full-scale, multicentre randomised controlled trial(RCT).\n\nHypothesis: Talc pleurodesis and ABPT demonstrate comparable efficacy in stopping PAL and facilitating chest drain removal within 5 days.\n\nDesign and subjects: This single-centre, two-arm, open-label pilot RCT will recruit 30 patients with SSP and PAL persisting ≥5 days. Eligible patients will be randomised in a 1:1 ratio to receive intrapleural talc pleurodesis or ABPT. Digital chest drain systems will continuously record air leak rates from 24 hours before randomization until 120 hours post-intervention, ensuring objective, real-time data capture. Patients will be followed till 90 days post-discharge.\n\nInterventions: Recruited subjects with PAL ≥5 days will be randomized in 1:1 ratio to receive talc pleurodesis or ABPT.\n\nMain outcome measures: The primary outcome is complete cessation of air leak and successful chest drain removal within 5 days after the intervention. Secondary outcomes include absolute and percentage changes in digitally measured air leak rates, duration of chest drainage, recurrence of ipsilateral pneumothorax, need for additional pleural interventions, and safety outcomes such as drain blockage and pleural infection.\n\nData analysis and expected results: Data will be analysed on an intention-to-treat basis for all randomised subjects with regression models adjusting for confounders. The pilot outcomes will inform sample size calculations and refine design parameters for the proposed full-scale multicentre RCT.",[26],[64,65,66],"Persistent air leak","talc pleurodesis","autologous blood patch therapy","2025-03-12",{"date":69,"type":38},"2025-03-19",{"date":71,"type":19},"2026-04-01",{"date":73,"type":19},"2029-03-31",{"name":75,"class":45},"Chinese University of Hong Kong",{"id":77,"slug":78,"hasResults":11,"nctId":79,"briefTitle":80,"officialTitle":81,"acronym":82,"eligibilityCriteria":83,"healthyVolunteers":11,"sex":15,"minAge":55,"maxAge":4,"enrollmentInfo":84,"targetDuration":4,"studyType":20,"phases":86,"briefSummary":87,"conditions":88,"keywords":90,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":96,"lastUpdatePostDateStruct":97,"startDateStruct":99,"completionDateStruct":101,"leadSponsor":103,"locationsCount":4},"100561405","chest-drain-insertion-assisted-by-virtual-reality-100561405","NCT06589739","Chest Drain Insertion Assisted by Virtual Reality","Drainage Thoracique Assisté Par Un Casque De Réalité Virtuelle","CASVIA","Inclusion Criteria:\n\n* Indication of chest drain insertion for pleural effusion or primary spontaneous pneumothorax\n* Patient who received clear and loyal information abotu the study protocol\n* Patient who consented to participate to the study\n* Patient aged 18 years old or older\n* Patient affiliated to the french health system\n\nExclusion Criteria:\n\n* Patient aged less than 18 years old\n* Patient in emergency situation\n* Patient with severe heart condition\n* Patient allergic to silicone\n* Patient with severe psychiatric or mental disorder\n* patient with binocular vision anomaly\n* patient with pacemaker or defibrillator\n* patient wearing a hearing aid that cannot be removed\n* Patients under the influence of alcohol or drugs, nausea, fatigue, emotional or anxiety disorders, migraine, headaches, infectious disease\n* Patient with past medical history of epilepsia or convulsion\n\n  \\-- Persons covered by articles L. 1121-5 and L1121-8 of the French Public Health Code:\n  * Pregnant, parturient or breast-feeding women,\n  * Persons of full age subject to a legal protection measure (guardianship, curatorship, safeguard of justice)\n  * adults unable to give their consent\n  * Persons deprived of their liberty by a judicial or administrative decision, persons under psychiatric care under articles L. 3212-1 and L. 3213-1.\n* Person able to give consent but unable to write\n* Person able to give consent but unable to read French\n* Patient unable to consent to the study",{"count":85,"type":19},40,[22],"Clinical study aiming to investigate the potential benefit of the use of virtual reality helmet as a distractor during chest drain insertion to alleviate patients\\' pain and anxiety",[25,26,89],"Pleural Effusion",[91,92,93,94,95],"virtual reality","chest drain","pain management","chest tube","anxiety management","2024-09-06",{"date":98,"type":38},"2024-09-19",{"date":100,"type":19},"2024-10-01",{"date":102,"type":19},"2025-10-01",{"name":104,"class":45},"Central Hospital, Nancy, France"]